AMICUS THERAPEUTICS, INC. Cash Flow Statement
FOLD / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
AMICUS THERAPEUTICS, INC. generated $33M in operating cash flow and $30M in free cash flow in FY2025. Free cash flow margin was 4.7% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$27.1M | -$56.1M | -$151.6M | -$236.6M | -$250.5M | -$276.9M | -$356.4M | -$349.0M | -$284.0M | -$200.0M | -$132.1M | -$68.9M | -$59.6M | -$48.8M | -$44.4M |
| Depreciation & Amortization | $7.5M | $8.5M | $7.9M | $5.3M | $6.2M | $8.8M | $4.8M | $4.2M | $3.6M | - | $1.8M | $1.5M | $1.7M | $1.7M | $1.6M |
| Operating Cash Flow | $33.1M | -$33.9M | -$69.1M | -$166.6M | -$202.5M | -$233.3M | -$250.4M | -$300.0M | -$213.7M | -$150.1M | -$100.1M | -$51.7M | -$45.8M | -$33.7M | -$194.6M |
| Capital Expenditures | $3.3M | $3.6M | $7.4M | $3.8M | $3.9M | $3.2M | $20.0M | $6.3M | $4.5M | $6.0M | $4.8M | $238.0K | $695.0K | $4.3M | $1.4M |
| Free Cash Flow | $29.8M | -$37.4M | -$76.5M | -$170.3M | -$206.4M | -$236.5M | -$270.4M | -$306.3M | -$218.2M | -$156.1M | -$105.0M | -$51.9M | -$46.5M | -$38.1M | -$196.0M |
| FCF Margin | 4.7% | -7.1% | -19.2% | -51.7% | -67.5% | - | - | - | -590.9% | -3148.4% | - | -4240.8% | -12806.9% | -206.8% | -914.6% |